Cannabis Stock News- Investing in Cannabis and Hemp Stocks : Investor Ideas #Potcasts 607, #Cannabis News and #Stocks on the Move; (Nasdaq: $HITI), (CSE: $FFNT.C), (OTCQX: $AAWH), (TSXV: $KHRN.V), (CSE: $DELC.C)

Investor Ideas #Potcasts 607, #Cannabis News and #Stocks on the Move; (Nasdaq: $HITI), (CSE: $FFNT.C), (OTCQX: $AAWH), (TSXV: $KHRN.V), (CSE: $DELC.C)

Delta, Kelowna, BC, October 7, 2021 (Investorideas.com Newswire) www.Investoride, as.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/100721-StocksToWatch.mp3

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/10071HITI-FFNT-AAWH-KHRN-DELC.asp

Hear Investor ideas cannabis potcast on iTunes

Hear the investor ideas potcast on Spotify

Today’s podcast overview/transcript:

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

In today’s podcast we look at a few public company announcements.

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF), a vertically-integrated, multi-state cannabis operator and retailer, today announced that it has signed definitive agreements on October 6, 2021, to acquire New England Cannabis Corporation, a best-in-class cannabis cultivator, with state-of-the-art facilities based in Holliston, Massachusetts. Upon closing, the Transaction is expected to be significantly accretive to the Company's EBITDA expectations for 2022 and will immediately scale 4Front's presence as a dominant wholesaler and producer in the State.

Massachusetts' competitive adult-use cannabis market is rapidly growing and 4Front has

already introduced its full suite of popular brands in the State which have achieved wide-scale consumer support. The Company expects the acquisition of NECC to significantly expand 4Front's strategic position and enable broader market penetration of 4Front's diverse range of low-cost, high-quality products and brands.

As a technological leader within the industry and one of the newest independent cannabis companies in Massachusetts, NECC's fully operational 55,000 sq. ft. licensed cultivation facility strengthens 4Front's expanding footprint in this important limited-license state. The Transaction will more than double 4Front's total flower canopy in Massachusetts to over 30,000 sq. ft, with further expansion potential for up to an additional 10,000 sq. ft. of canopy, and will approximately triple 4Front's kitchen, processing and distribution space. The NECC facility will supplement the products sold through 4Front's existing "Mission" dispensaries and further strengthen the Company's presence in the Massachusetts wholesale market.

"The acquisition of New England Cannabis reinforces our core thesis of bringing scaled, low-cost production and operational depth to attractive, nascent, adult-use cannabis markets" said Leo Gontmakher, Chief Executive Officer of 4Front. "The addition of NECC's impressive operations will increase our canopy, kitchen capacity, and add to our extraction capabilities overnight, greatly bolstering our position in the Massachusetts market to become a leading wholesaler of our full suite of products and brands. This acquisition firmly anchors our foothold in the Northeast, and NECC's state-of-the-art facility will help to drive our growth in the years ahead as we execute on our goal of achieving dominant market share in every geography we operate. I look forward to working with NECC's seasoned team and leveraging their extensive operational experience as we continue to scale."

Ascend Wellness Holdings, Inc. (CSE: AAWH.U) (OTCQX: AAWH), a multi-state, vertically-integrated cannabis operator, and Edie Parker, a luxury fashion brand known for its vintage-inspired clutches and handbags, today announced the debut of Flower by Edie Parker pre-rolls in Massachusetts. In May, AWH and Edie Parker announced an exclusive wholesale licensing agreement to bring Flower by Edie Parker products to emerging adult-use markets in Massachusetts and Illinois. The coveted West Coast brand first expanded beyond California earlier in March by launching sales in Colorado.

Flower by Edie Parker is now available at AWH's flagship Boston location at 272 Friend St and became available statewide via AWH's distribution network on October 3rd. By early November, patients and consumers in Illinois will also be able to purchase Flower by Edie Parker pre-rolls at all eight of AWH's retail locations. Elegantly packaged and sold in new 'Best Buds' twin packs of 0.5 gram pre-rolls, customers can choose from three distinct offerings including:

● Early Bird, a sativa product featuring a light and creative flavor that pairs well with morning hike or mid-afternoon coffee.

● Happiest Hour, a hybrid product that's party perfect, ideal for hanging with friends or a night out dancing.

● Nightcap, an indica perfect for evening or any relaxation ritual.

"Edie Parker's brand is known for its elegant aesthetic and devotion to delivering top-notch cannabis products and accessories," said AWH Founder and CEO Abner Kurtin. "We believe Edie Parker will elevate and expand the selection at AWH stores, enticing new customers and delighting returning ones. Bringing this exceptional West Coast brand out East is part of our ongoing strategy of developing deeper relationships with customers in our existing markets, and we are excited to bring Edie Parker's products to this increasingly sophisticated audience."

In addition to debuting its pre-rolls in Massachusetts and Illinois, Edie Parker will offer a curated assortment of the brand's vibrant and artisanal cannabis accessories wherever their products are sold and plan to launch a number of brand activations at AWH stores over the next month. AWH pop-ups will include Edie Parker's acclaimed branding featuring imagery, banners and whimsical activations similar to the brand's most recent New York Fashion Week event.

"Our brand is all about celebrating cannabis with others, and we are thrilled to share our distinctive line of products with two new communities of consumers," said Brett Heyman, Founder of Flower by Edie Parker. "The idea behind our Best Buds pre-rolls is to share premium cannabis with your best bud. No matter the occasion, our line of products was created to surprise and delight. The AWH team shares our commitment to bringing fun yet polished cannabis experiences to the everyday consumer, and our partnership enables us to show even more consumers how to be loud and proud about their love for the plant."

A recent opinion article discussed the many benefits of the Massachusetts’ cannabis model commenting that the state and how other states are taking noticed as “Massachusetts has taken the lead by developing a regulatory framework that protects both the state and consumers by creating an environment that reflects a healthy balance between centralized licensing and enforcement authority — housed in the Cannabis Control Commission (CCC), and local autonomy in the selection and vetting of the participants and applicable zoning enforcement.”

Khiron Life Sciences Corp. (TSXV: KHRN)(OTCQX: KHRNF), a vertically integrated international cannabis leader with core operations in Latin America and Europe, announced that the Company presented results from its first research study including 1,453 patients from Khiron-owned Zerenia Clinics at the 29th International Pain Conference in Barranquilla, Colombia, organized by ACED, the Colombian chapter of the International Association for the Study of Pain (IASP).

The study, entitled "Prescription patterns and clinical outcomes in a cohort of patients receiving progressive therapy with cannabinoids for medical use in Colombia", is a longitudinal, retrospective cohort study including 1,453 patients receiving treatment with medical cannabis at Khiron-owned clinics in Colombia, Zerenia and ILANS.

The scope of research was to capture patient-reported outcome measures (PROMS) and patient-reported experience measures (PREMS) of general efficacy, adherence, and side effects of oral formulations ranging in cannabinoid content for the treatment of different health conditions with a diverse patient base over a twelve-month period.

The research protocol was reviewed and approved by the Scientific Institutional Committee and the Research Ethical Committee of the Universidad del Bosque, in Colombia, one of the leading institutions on medical research in the region.

Demographic results reported most patients were female (73%) with and average age of 59.3 years old, which is in strong contrast with results arising from Project T21, the UK's first medical cannabis registry Khiron Life Sciences has been supporting since its foundation in 2019. Patients in the study were mainly diagnosed with chronic, non-cancer pain (77%), followed by nausea and vomiting (8%), insomnia (6%), anxiety (5%), spasticity and depression, among others and up to 68 % of patients had their medical cannabis prescription cost covered by the Social Security in Colombia. Study results show a patient-reported positive clinic response in more than 80% of participants with only minor side-effects associated to the treatment.

"Scientific research and data are key to convincing doctors and policy makers all over the world about the benefits of medical cannabis to treat conditions that are prevalent in every society and market we are targeting. After one year of compiling information and having gone through a very detailed approval process, we are very proud to share the results from this first-of-its-kind clinical study in Latin America with such a significant patient base. This is just the beginning of our ongoing research program. We are looking forward to sharing the outcomes of this first cohort study with the international medical audience through peer-reviewed, specialized publications so doctors all over the world can continue to drive prescription growth safely and responsibly ", commented Alvaro Torres, Chief Executive Officer and Director of the Company.

Delic Holding Corp Inc. (CSE: DELC) (OTCQB: DELCF) announced that Delic Labs has applied for a Health Canada 56 Research Exemption that would allow the scientists to perform research and tests on a host of compounds outside of psychedelic mushrooms, including MDMA and LSD. The lab currently holds a 56 Research Exemption for chemistry analytics on psilocybin mushrooms.

Additionally, the lab has applied for a Dealer's License and intends to eventually commercialize its psilocybin research and associated intellectual property (IP) for medical and research purposes. Some of the work would include researching extraction of pharmaceutically relevant compounds from psychedelic mushrooms and turning those extracts into medical products. Delic Labs will also synthesize non-naturally occurring compounds as part of its ongoing med-chem pipeline.

Delic Labs is a federally authorized psilocybin and cannabis research laboratory focused on extraction, analytical testing, and chemical process development. Delic Labs serves as the engine for the Delic platform, conducting research and developing innovative product lines and intellectual property, including psilocybin vaporization technology for future distribution across the Company's physical footprint and licensed psychedelic wellness clinics in the United States.

Matt Stang, co-founder and CEO of Delic Corp, stated, "Never before has a lab been authorized to test psychedelic compounds such as MDMA and LSD with the opportunity to create new medicines for the millions suffering from debilitating conditions like depression, anxiety, PTSD and Parkinson's disease. Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market."

"Once we secure this 56 Research Exemption together with the Dealer's License, Delic Labs will become the leader in safety testing of psychedelic compounds to ensure the highest standards and quality control," said Dr. Markus Roggen, co-founder of DELIC Labs. "We will greatly expand our capabilities to work with other banned substances, such as MDMA and LSD, along with psilocybin to develop new psychedelic drugs for medical and research purposes. We believe we are on the cusp of understanding the breadth of what is possible with psychedelics and medicine."

Founded by Dr. Roggen, an award-winning chemist, and UBC Professor, Dr. Glenn Sammis, Delic Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization. Delic Labs is one of a handful of licensed psilocybin research labs in Canada and has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry. Delic Labs is also a leading cannabis analytical and research company boasting clients that include some of the largest brands in the world.

High Tide Inc. (TSXV: HITI) (Nasdaq: HITI), a retail-focused cannabis company enhanced by the manufacturing of proprietary and licensed consumption accessories, announced that it is taking another step towards solidifying itself as a major player within the global e-commerce marketplace for hemp-derived CBD products, by entering into a definitive agreement, pursuant to which High Tide will acquire 80% of Enigmaa Ltd., operating as Blessed CBD, for £9.06 Million, and will have a three-year option to acquire the remaining 20% of Blessed at any time.

Founded in 2019 with its headquarters in Scotland, Blessed has quickly grown to become one of the most popular brands for hemp-derived CBD products across the U.K., including CBD oils, creams, gummies, and capsules. In 2020 Blessed had almost 5 million site visits and an average order value of approximately £75. Blessed's founder and Chief Executive Officer, Vithurs Thiru (known more commonly as "V"), will join the High Tide team as Senior Manager of Search (SEO) of the Company, and will help grow High Tide's CBD business globally.

"I'm very pleased to announce the addition of Blessed CBD, the U.K.'s top CBD brand as designated by several prominent publications, into the High Tide family. We continue to increase our online prowess by adding asset-light businesses to our growing global e-commerce portfolio. Blessed is a fully direct-to-consumer platform that generates industry-leading gross margins as well as EBITDA margins that will continue to add to our consolidated margin profile," said Raj Grover, President and Chief Executive Officer of High Tide. "This acquisition marks our entry into the highly lucrative and rapidly-growing U.K. CBD space which we expect to serve as a launching pad for High Tide to further penetrate the E.U. market for hemp-derived CBD products, while also taking advantage of cross-selling opportunities related to our in-house product lines. I have been very impressed with the amazing business that V has been able to build within just two years, and look forward to welcoming him and the rest of the Blessed team into our company," added Mr. Grover.

"Blessed CBD has experienced rapid growth and success from inception, and our goal is to become the most sought-after CBD brand globally. Our team is super excited to be joining hands with Raj, and by leveraging High Tide's existing resources and reach, I couldn't be more excited about the future," said Vithurs Thiru, CEO of Blessed. "I look forward to working with Raj and his team to accelerate the digital presence of High Tide's brands, and to position High Tide as one of the leading vertically-integrated cannabis companies in the industry. This acquisition provides unparalleled opportunities for growth to serve our current and future customers, expand into emerging new markets, and introduce new products unmatched in quality," added Mr. Thiru.

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com

podcasts visit: https://www.investorideas.com/Audio/.

The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms available.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com